NICE TAs

29/04/2020

TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy

29/04/2020

TA517: Avelumab for treating metastatic Merkel cell carcinoma

28/04/2020

TA518: Tocilizumab for treating giant cell arteritis

28/04/2020

TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

28/04/2020

TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

28/04/2020

TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

28/04/2020

TA513: Obinutuzumab for untreated advanced follicular lymphoma

28/04/2020

TA568: Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)

28/04/2020

TA534: Dupilumab for treating moderate to severe atopic dermatitis

28/04/2020

TA521: Guselkumab for treating moderate to severe plaque psoriasis

28/04/2020

TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

28/04/2020

TA546: Padeliporfin for untreated localised prostate cancer

28/04/2020

TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

28/04/2020

TA565: Benralizumab for treating severe eosinophilic asthma

28/04/2020

TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs

28/04/2020

TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

28/04/2020

TA585: Ocrelizumab for treating primary progressive multiple sclerosis

28/04/2020

TA542: Cabozantinib for untreated advanced renal cell carcinoma

28/04/2020

TA523: Midostaurin for untreated acute myeloid leukaemia

28/04/2020

TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia